Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

J&J’s Q3 Profits Increased With Higher Sales In Consumer, Pharmaceutical & Medical Devices Units

By John F. Heerdink, Jr.

Reportedly, Johnson & Johnson (JNJ) sold $502 million of its Covid-19 vaccine in the third quarter. The Pharma giant reported adjusted EPS of $2.60 per share versus $2.35 expected. Revenue stood at $23.34 billion versus $23.72 billion expected. The company maintained its Covid vaccine sales outlook for the year at $2.5 billion.

The consumer unit, which includes products such as Listerine and Neutrogena face wash, reported $3.7 billion in revenue, an increase of 5.3% from a year earlier. J&J’s pharmaceutical business, which developed the single-shot Covid vaccine, generated $12.9 billion in revenue, a 13.8% year-over-year increase. J&J increased its full-year earnings guidance to between $9.77 per share and $9.82 per share, from its earlier estimates of $9.60 to $9.70 per share. It expects sales to range from $94.1 billion to $94.6 billion, an increase from previous guidance of $93.8 billion to $94.6 billion. Its medical device unit was hit hard last year as the coronavirus pandemic forced Americans to stay home and hospitals to postpone elective surgeries, reported $6.6 billion, an 8% rise.

In a press release, Gorsky said the financial results “demonstrate solid performance across Johnson & Johnson, driven by robust above-market results in Pharmaceuticals, ongoing recovery in Medical Devices, and strong growth in Consumer Health.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

(Read Original Story: J&J Covid vaccine added $502 million to third-quarter sales in CNBC)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us